ARGX stock forecast, quote, news & analysis
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases... Show more
Why argenx (ARGX) Stock Is Down -11.6% in the Last 30 Days
Key Takeaways
- ARGX shares have declined roughly 11.6% over the last 30 days, falling from about $990 in mid-September to around $876.
- The move was driven by argenx's October 8, 2026 announcement that it is discontinuing its Phase 3 UNITY study of subcutaneous efgartigimod in Sjögren's disease after an interim futility analysis.
- The setback removes a potential blockbuster indication; UBS had modeled up to $3.5 billion in peak annual sales for Vyvgart in Sjögren's disease.
- Positive Phase 2 FB102 data in celiac disease, announced the same day, only partially offset the market's reaction.
- Over the last quarter the stock is roughly flat, reflecting a mid-August rally on myositis data that has since been given back.
argenx (ARGX) Company Overview and Market Position
argenx SE is an Amsterdam-based global immunology company focused on developing antibody-based medicines for severe autoimmune diseases. The company's flagship product is Vyvgart (efgartigimod alfa), a first-in-class neonatal Fc receptor (FcRn) blocker approved for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). A subcutaneous formulation, Vyvgart Hytrulo, extends the franchise across multiple markets, and the drug generated $4.2 billion in global revenue in 2025.
argenx has built its business around expanding the Vyvgart franchise into new indications while advancing earlier-stage pipeline assets. The company's second-quarter 2026 product net sales reached $1.516 billion, up 60% year over year, and it held $5.2 billion in cash and current financial assets as of June 30, 2026. Investors follow ARGX closely because its growth narrative depends heavily on clinical readouts that can expand the franchise's addressable market.
argenx (ARGX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, ARGX has declined about 11.6%, moving from a closing level near $990 on September 18, 2026 to approximately $876. The bulk of that decline occurred on October 8, when shares fell roughly 11.8% in a single session — the stock's worst day since December 2023 — after the company halted the Phase 3 UNITY study in Sjögren's disease. Shares touched an intraday low near $788 before stabilizing and recovering into the $800s and, most recently, back above $870.
Looking at the last quarter, the picture is much more balanced. Three months ago the stock closed near $846, meaning ARGX is essentially flat (up roughly 3%) over the quarter despite the sharp recent pullback. The quarterly trend was a round trip: shares rallied more than 15% in mid-August on positive myositis trial data, climbed to a 52-week high of $1,072.75 in early September, and then steadily gave back those gains before the October setback accelerated the decline.
What Drove ARGX Stock Price in the Last 30 Days
The dominant catalyst was the October 8, 2026 decision to discontinue the Phase 3 UNITY study of efgartigimod subcutaneous in adults with moderate-to-severe Sjögren's disease. An independent data monitoring committee recommended stopping the trial for futility, concluding it was unlikely to meet its primary endpoint — change in systemic disease activity at Week 48. Safety was consistent with the drug's established profile, and no new safety signals were identified.
The market reaction reflected the size of the opportunity being removed. UBS analysts, who had modeled peak annual sales of $3.5 billion for Vyvgart in Sjögren's disease, said the discontinuation pointed to very little efficacy "if any" rather than a near miss. RBC Capital Markets analyst Luca Issi described the setback as "clearly unfortunate" but argued the selloff was "way overdone," noting it removed what he viewed as the stock's most compelling 2027 catalyst. Other firms took a measured view: Bernstein reiterated a Buy rating, Wedbush lowered its price target to $1,130, and H.C. Wainwright maintained a Buy rating with a $1,202 target.
The negative news overshadowed positive same-day data. argenx reported that its Phase 2 FB102 trial in celiac disease met its primary endpoint with a statistically significant, clinically meaningful effect versus placebo, and the company plans to advance FB102 into Phase 3 development. FB102 came from argenx's $2.2 billion acquisition of Forte Biosciences, completed in August 2026.
What Drove ARGX Stock Performance Over the Last Quarter
The quarterly narrative was defined by pipeline momentum followed by a sharp reversal. On August 17, 2026, argenx reported that its Phase 3 ALKIVIA study in autoimmune myositis met its primary endpoint, triggering a double-digit rally that carried the stock to its 52-week high. That enthusiasm reflected investors' confidence in the company's strategy of broadening the Vyvgart franchise into new autoimmune indications.
Through September, however, the stock drifted lower as the broader biotech tape cooled and attention turned to the high-stakes Sjögren's disease readout. The October futility stop then crystallized a key risk that has long hung over the name: concentration in the Vyvgart franchise, which accounts for essentially all of the company's product revenue. The quarter thus ended roughly where it began, with the gains from the myositis readout largely erased by the Sjögren's disappointment.
Trending AI Robots
For traders tracking names like ARGX, Tickeron's Trending AI Robots page offers a curated view of its top-performing automated trading bots. Tickeron operates hundreds of AI trading bots that collectively trade thousands of tickers, but only the strongest and most relevant bots are featured in this section. These bots vary widely in strategy, holding timeframe, and performance metrics, giving users a range of approaches to explore. Browsing the page can help traders identify data-driven signals and strategies that match their own objectives.
ARGX Stock Forecast Drivers: What Investors Should Watch Next
Near-term attention centers on argenx's third-quarter 2026 results, scheduled for October 22, where management is expected to address the UNITY outcome and outline plans for the remaining pipeline. The next major clinical catalyst is the EMPASSION readout for empasiprubart in CIDP, guided for the fourth quarter of 2026; Morgan Stanley has highlighted this asset as the company's most significant potential upside driver. Additional milestones include the ADVANCE-NEXT study in primary immune thrombocytopenia in the first half of 2027 and the advancement of FB102 in celiac disease.
Key risks include continued concentration in the Vyvgart franchise, competitive dynamics in autoimmune disease — including Novartis's NVS ianalumab, which has shown positive results in Sjögren's disease — and execution across late-stage trials. As always with clinical-stage biotechs, trial outcomes can move the stock sharply in either direction, and investors should weigh pipeline risk against the strength of the existing commercial franchise.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
ARGX's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ARGX turned positive on October 21, 2026. Looking at past instances where ARGX's MACD turned positive, the stock continued to rise in 39 of 49 cases over the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARGX's RSI Indicator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on ARGX as a result. In 63 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in 215 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
ARGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The 10-day moving average for ARGX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 63%.
The Aroon Indicator for ARGX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 12 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.892) is normal, around the industry mean (3.498). P/E Ratio (33.413) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.189) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (12.330) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of antibody-based medicines
Industry Biotechnology